- Details
- In this conversation, Neal Shore, Alicia Morgans and Chuck Ryan discuss their views on what the next “big thing” is in prostate cancer and exciting new developments in 2019. These advancements include a renewed look at the patient’s experience and point of view to integrate into treatment decision making. The group sees continued research in race and genetic disparities and how these factors effec...
|
- Details
- Josh Meeks and Alicia Morgans discuss the clinical treatment of high-risk NMIBC in a BCG rationed era. Biographies: Josh J. Meeks, MD, PhD, Assistant Professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, Chicago Illinois Alicia Morgans, MD, MPH , Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern...
|
- Details
- Josh Meeks reviews the SWOG 1806 study protocol with Alicia Morgans. T he SWOG 1806 study , Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer is expected to begin enrollment in May 2019. This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle...
|
- Details
- Sia Daneshmand joins Ashish Kamat in a conversation on the phase III trial comparing blue light flexible cystoscopy with white light flexible cystoscopy for the detection of bladder cancer during surveillance. This study shows significant improvement of the detection of patients with recurrent bladder cancer and for the detection of carcinoma in situ, detecting lesions that are missed with white l...
|
- Details
- Cora Sternberg joins Alicia Morgans in a discussion on practice transforming presentations in prostate cancer from the 2019 GU ASCO meeting. Among the presentations overviewed is the ARAMIS trial in nonmetastatic castration-resistant prostate cancer (mnCRPC) where Cora highlights its similarities to the PROSPER and SPARTAN trials. They discuss progression-free survival in the second update on the...
|
- Details
- Matthew Galsky and Alicia Morgans share in a discussion on combination and maintenance strategies for muscle-invasive and metastatic bladder cancer and a number of reasons for combining immunotherapy with immune checkpoint blockade. These reasons include the concept of immunogenic cell death, depletion of suppressive immune cell subsets and independent drug action. Biographies: Matthew Galsky, MD,...
|
- Details
- President of KCCure, Dena Battle joins Monty Pal in a discussion on the management of de novo metastatic kidney cancer and the change in practice from cytoreductive nephrectomy to an option of systemic therapy driven by the results of CARMENA trial. Dena shares the patients perspective on this treatment paradigm which comes from a patient survey her organization put forth answering the question of...
|
- Details
- Petros Grivas discussed Neeraj Agarwal's insights about the latest prostate cancer study results that will impact patient care as presented at ASCO GU 2019. The ARAMIS trial evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. Darolutamide is a structurally unique androgen-receptor antagonist that is under develop...
|
- Details
- Charles Ryan and Michael Hofman share in a discussion on the use of new imaging techniques in prostate cancer, the sensitivity of imaging and the use of theranostics PSMA targeted therapies for metastatic castrate-resistant prostate cancer. Michael Hofman details the quick advance of PSMA imaging in Australia. He highlights PSMA tracers including Gallium-68 and PSMA-Based [18F]DCFPyL PET/CT and th...
|
- Details
- Alicia Morgans interviews Andrea Apolo who details the trial design and current status of the Phase III adjuvant AMBASSADOR trial for patients with high-risk muscle-invasive bladder cancer (MIBC) and the need to develop additional treatment options for patients who are resistant to chemotherapy and develop recurrent disease. The AMBASSADOR trial aims to answer the question if there is a benefit to...
|
